Paolo Tarantino
Clinical Research Fellow DFCI
Paolo Tarantino is a medical oncologist and clinical researcher. He’s currently pursuing an advanced fellowship at Dana-Farber Cancer Institute and at Harvard Medical School (Boston, MA). His research focuses on breast oncology, the development of novel ADCs and validation of quantitative biomarkers to predict the activity of ADCs.
Seminars
Re-join your expert speakers in a closing panel discussion as they explore the impact of ADC combination on the oncology treatment landscape, best rationale to select appropriate ADC combination partners, ability to combat ADC payload resistance.
Make sure to come with your thoughts and questions prepared!
- Bringing in the clinician perspective to understand the efficacy performance from ADCs administered sequentially
- Assessing real-world data to analyse the impact of current ADC sequence therapies
- ADCs biomarkers: Exploring data demonstrated so far and connection to ADC sequences
As ADCs become more prevalent in a busy clinical landscape, the role of ADC combinations and sequencing is increasingly important to deliver enhanced therapeutic benefit to patients
Take part in the Combination Seminar Day to delve into clinical combination design and performance, understand the potential of dual-payload conjugates and sequencing to combat payload resistance, and discover science-driven approaches to select the optimal combination partner to optimise your ADC combination strategy and performance
